Achieve Life Sciences Inc
$ 5.10
6.03%
17 Apr - close price
- Market Cap 271,524,000 USD
- Current Price $ 5.10
- High / Low $ 5.30 / 4.75
- Stock P/E N/A
- Book Value 0.40
- EPS -1.25
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.85 %
- ROE -2.58 %
- 52 Week High 6.03
- 52 Week Low 1.96
About
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and internationally. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$14.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-26 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-13 | 2023-11-09 | 2023-08-14 | 2023-05-09 |
| Reported EPS | -0.28 | -0.28 | -0.37 | -0.37 | -0.36 | -0.36 | -0.25 | -0.26 | -0.26 | -0.34 | -0.43 | -0.5 |
| Estimated EPS | -0.2771 | -0.24 | -0.37 | -0.3657 | -0.36 | -0.26 | -0.23 | -0.24 | -0.31 | -0.38 | -0.42 | -0.69 |
| Surprise | -0.0029 | -0.04 | 0 | -0.0043 | 0 | -0.1 | -0.02 | -0.02 | 0.05 | 0.04 | -0.01 | 0.19 |
| Surprise Percentage | -1.0466% | -16.6667% | 0% | -1.1758% | 0% | -38.4615% | -8.6957% | -8.3333% | 16.129% | 10.5263% | -2.381% | 27.5362% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACHV
2026-04-17 01:39:19
Achieve Life Sciences has appointed Dr. Cindy Jacobs and Dr. Jay Moyes to its Board of Directors, bringing extensive experience in pharmaceutical development, regulatory affairs, and financial management. This move coincides with the company securing a non-dilutive financing commitment of up to $354 million from a syndicate of leading healthcare investors. This funding, a significant portion of which is committed for development milestones, will support the ongoing clinical development and potential commercialization of Cytisinicline, Achieve's lead product for smoking cessation.
2026-04-16 20:40:01
Achieve Life Sciences has secured up to $354 million in funding through a private placement, with $180 million upfront and the potential for an additional $174 million from milestone-driven warrants. The company plans to use these proceeds to fund a Phase 3 trial for e-cigarette cessation, commercialize cytisinicline, and for general corporate purposes. Alongside this financing, Richard Stewart will step down as CEO, and Andrew Goldberg, MD, will take over the role, bringing new leadership and investor representation to the board.
2026-04-16 13:40:01
Achieve Life Sciences (ACHV) has announced a private placement that could raise up to $354 million. The funding will support the company's efforts in advancing its cytisinicline smoking cessation treatment. This financial move aims to provide the necessary capital for ongoing development and potential commercialization.
2026-04-16 13:10:21
Achieve Life Sciences has appointed Andrew D. Goldberg, MD, as its new Chief Executive Officer and a member of its Board of Directors, effective after the closing of a recent financing round. Dr. Goldberg brings extensive medical, investment, and commercial strategy experience, and will lead the company in advancing cytisinicline, a potential new treatment for nicotine dependence. The company also added Lucian Iancovici, MD, and Aaron E. Royston, MD, to its Board, strengthening its leadership as it prepares for potential FDA approval and commercialization.
2026-04-16 13:01:00
Achieve Life Sciences has secured up to $354 million in financing through a private placement to fund the development and commercialization of cytisinicline, a treatment for nicotine dependence. The financing includes an initial $180 million and up to an additional $174 million from milestone-driven warrants, with prominent healthcare investors leading the deal. The funds will support a Phase 3 clinical trial for cytisinicline in e-cigarette cessation and general corporate purposes, and Dr. Andrew D. Goldberg has been appointed as the new CEO.
2026-04-16 12:40:01
HC Wainwright reiterated a "Buy" rating for Achieve Life Sciences (ACHV) with a $12 price target, suggesting a 238% upside. Despite this, analyst opinions are mixed, with MarketBeat showing an average "Moderate Buy" rating and a $15.50 target, while Weiss Ratings maintains a "Sell." The company reported a Q EPS loss of $0.28, missing estimates, and institutional investors like Franklin Resources Inc. have significantly increased their holdings.
